BioSpace News Archive

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Company will present an overview of the company at the Piper Jaffray 31st Annual Healthcare Conference

Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today Dr. John Ross, Ph.D., vice president of protein therapeutics, will give a presentation highlighting the potential of the company’s proprietary therapeutic platform Immuno-STAT™

Company Unveils New Initiative, ProFound AI Powered by Panorama, which will Enable Breast Imaging Intelligence Technology to Correlate Findings Over Time

Tauriga Sciences, Inc. confirmed that it will be an Exhibitor at The Hemp World Expo, which will take place on January 18-19, 2020 at the following venue: The Atlanta Expo Center North/ Atlanta, Georgia.

Accelerate Diagnostics, Inc. announced that Louise Francesconi has been appointed to the company’s Board of Directors.

Research Foundation to Cure AIDS (RFTCA) announced plans to nucleate its AIDS cure incubator at Northwell Health in the former AIDS ward of St. Vincent’s Hospital in New York City, where thousands suffered and died of AIDS.

Carestream Health demonstrated cutting-edge medical imaging technology designed to improve workflow and enable better diagnosis at the annual meeting of the Radiological Society of North America.

Apollo Endosurgery, Inc. announced that company management will present at the 12th Annual LD Micro Main Event investor conference at the Luxe Sunset Boulevard Hotel in Los Angeles, California, on Tuesday, December 10, 2019.

PellePharm, Inc., a BridgeBio Pharma, Inc. company, announced the completion of enrollment for its pivotal Phase 3 clinical trial of Patidegib Topical Gel 2% vs. vehicle gel in patients with Gorlin Syndrome.

Closing conditions waived - Amended & Restated Partnership Agreement is now closed